Search All UT System Experts

A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: A gynecologic oncology group study

David L. Tait, John A. Blessing, James S. Hoffman, Kathleen N. Moore, Nick M. Spirtos, Jason A. Lachance, Jacob Rotmensch, David S. Miller

Research output: Contribution to journal › Article › peer-review

37 Scopus citations

Fingerprint

Dive into the research topics of 'A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: A gynecologic oncology group study'. Together they form a unique fingerprint.

Medicine & Life Sciences